Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor

The present study evaluated the distribution of doxorubicin (DOX), as a fluorescent marker and an anti-tumor agent, to a lung tumor region following intrapulmonary administration. Using a Liquid MicroSprayer®, DOX (400 μg/kg) was administered to mice with B16F10, which are murine melanoma cells that induce metastatic lung tumor. DOX concentrations in the lung following intrapulmonary administration were markedly higher than those following intravenous administration. On the other hand, DOX concentrations in serum following intrapulmonary administration were significantly lower than those following intravenous administration. DOX fluorescence after intrapulmonary administration was widely observed in the tumor region with P-glycoprotein expression. In contrast, DOX was not observed in the tumor region following intravenous administration. DOX administered intrapulmonarily suppressed the tumor growth than case of intravenous administration. These results indicate that intrapulmonary administration can efficiently deliver anti-tumor agents for lung cancer.

Figure optionsDownload as PowerPoint slide